648 results on '"Negoro, S."'
Search Results
2. Structure of 6-aminohexanoate-oligomer hydrolase NylC precursor, D122G/H130Y/T267C mutant
3. Structure of 6-aminohexanoate-oligomer hydrolase NylC precursor, H130Y/N266A/T267A mutant
4. Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer
5. Quality of life and disease-related symptoms in previously treated Japanese patients with non-small-cell lung cancer: results of a randomized phase III study (V-15-32) of gefitinib versus docetaxel
6. Phase III trial of docetaxel plus gemcitabine versus docetaxel in second-line treatment for non-small-cell lung cancer: results of a Japan Clinical Oncology Group trial (JCOG0104)
7. High efficiency mixing by the use of cross-linked micro capillary fluid filter
8. Biodegradation of nylon oligomers
9. CORRELATIVE STUDY OF LOW SERUM CREATININE AND HEMATOLOGICAL TOXIC EFFECTS IN JAPANESE PATIENTS WITH OVARIAN CANCER TREATED BY DOSE DENSE TC THERAPY
10. SELF-ASSESSMENT SYSTEM OF FEBRILE NEUTROPENIA (FN) BY PATIENTS RECEIVING AMBULATORY CHEMOTHERAPY FOR SOLID TUMOR
11. A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
12. Phase I–II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer
13. Dose-intensive chemotherapy in extensive-stage small-cell lung cancer
14. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
15. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumors
16. Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI)
17. Phase I study of combined radiation, hyperthermia and intra-arterial carboplatin for local recurrence of cervical cancer
18. Phase I study of combined radiation, hyperthermia andintra-arterial carboplatin for local recurrence of cervical cancer
19. A phase I intermittent dose-escalation trial of ZD1839 (Iressa™) in Japanese patients with solid tumors.
20. A phase II study of induction chemotherapy (CT) with CPT-11 and cisplatin followed by thoracic radiation (TRT) combined with weekly CPT-11 in patients with unresectable stage III non-small-cell lung cancer (NSCLC).
21. Simple ELISA using Polyclonal Antibody and Lectin for Determination of Soluble Chitosan - Like Polysaccharide in Bacterial Culture
22. Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., D122V muntant
23. Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72.
24. Structure of 6-aminohexanoate-oligomer hydrolase from Arthrobacter sp. KI72., H130Y muntant
25. Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)
26. Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
27. Enzymes Active on Unnatural Synthetic Compounds: Nylon Oligomer Hydrolases Controlled by a Plasmid and their Cloning
28. 520P - A phase II study to evaluate abscopal effect by palliative radiation therapy in nivolumab treatment for pretreated non-small cell lung cancer (HANSHIN 0116)
29. 1501TiP - Afatinib (AFA) plus bevacizumab (BEV) combination after osimertinib (OSIME) failure for aDvanced EGFR-mutant non-small cell lung cancer (NSCLC): A multicenter prospective single arm phase II study (ABCD-study)
30. Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient
31. 423P - Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)
32. THORACOSCOPIC PLEURAL BIOPSY UNDER LOCAL ANESTHESIA USING A 2MM LAPAROSCOPE
33. Monitoring Egfr T790M Using Plasma Dna in Lung Cancer Patients Treated with Egfr Tyrosine Kinase Inhibitor in a Prospective Observational Study
34. PO-0681: Improved prediction of severe radiation pneumonitis by combining V20, VS5, pulmonary fibrosis on CT, and age
35. The Influence of Body Mass Index on Severe Neutropenia with Dose-Dense Paclitaxel/Carboplatin in Ovarian Cancer Patients
36. Phase I Study of Ombrabulin in Combination with Paclitaxel + Carboplatin Administered Every 3 Weeks to Japanese Patients
37. A Phase II Study of Pemetrexed in Chemotherapy-naive Elderly Patients Aged >=75 years with Advanced Non-squamous Non-small-cell Lung Cancer (HANSHIN Oncology Group 003)
38. Crystal structure of 6-aminohexanoate-dimer hydrolase S112A/G181D/R187S/H266N/D370Y mutant complexd with 6-aminohexanoate
39. Crystal structure of 6-aminohexanoate-dimer hydrolase G181D/R187G/H266N/D370Y mutant
40. 6-aminohexanoate-dimer hydrolase S112A/G181D/R187A/H266N/D370Y mutant complexd with 6-aminohexanoate
41. A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. CPT-11 Lung Cancer Study Group
42. A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy
43. Abstract P6-07-30: The clinical significance of pathologic complete response using different definitions after neoadjuvant chemotherapy in HER2 positive breast cancer patients according to hormonal receptor status.
44. Oral S-1 and Carboplatin Plus Bevacizumab with Maintenance S-1 and Bevacizumab for Chemo-Naïve Patients with Non-Squamous Non-Small-Cell Lung Cancer
45. A Phase II Study of Pemetrexed in Chemotherapy-Naive Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003
46. The Clinical Significance of Pathologic Complete Response (PCR) after Neoadjuvant Chemotherapy and Treatment Strategy in HER2 and Hormonal Receptor Positive (HR+) Breast Cancer Patients
47. Randomized Phase III Study Comparing Etoposide and Cisplatin (EP) with Irinotecan and Cisplatin (IP) Following EP Plus Concurrent Accelerated Hyperfractionated Thoracic Radiotherapy (EP/AHTRT) for the Treatment of Limited-Stage Small-Cell Lung Cancer (LD-SCLC): JCOG0202
48. A Phase II Study of Pemetrexed in Chemotherapy-Naïve Elderly Patients with Advanced Non-Squamous Non-Small-Cell Lung Cancer: Hanshin Oncology Group 003
49. Structure of 6-aminohexanoate-oligomer hydrolase
50. 9109 POSTER A Phase II Study of Pemetrexed in Heavily Pretreated Non-squamous Non Small Cell Lung Cancer – HANSHIN Oncology Group 001
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.